A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs BPN 14770 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Tetra Discovery Partners
  • Most Recent Events

    • 19 Dec 2016 According to a Tetra Discovery Partners media release, this trial was conducted with the support of the National Institute of Health through a grant from the National Institute on Aging (AG054243) and funding from the Alzheimer's Drug Discovery Foundation.
    • 19 Dec 2016 Post hoc pooled results published in a Tetra Discovery Partners media release.
    • 19 Jul 2016 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top